Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to Immune Checkpoint Blockade is Influenced by HLA-I Genotype.

Cancer discovery - 1 Feb 2018

Abstract excerpt

Maximal HLA-I loci heterozygosity is linked to improved survival after immune checkpoint blockade.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CTLA-4 Antigen
Share to Genotype
Share to Immunotherapy
Share to Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Programmed Cell Death 1 Receptor

Source

Identifiers

PMID: 29247014
DOI: 10.1158/2159-8290.CD-RW2017-236

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to Immune Checkpoint Blockade is Influenced by HLA-I Genotype.PMID 29247014Read ↗

HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started.Semantic proximity Read ↗

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapySemantic proximity Read ↗

HLA Genotype is Associated With Clinical Outcomes to anti-PD1 Therapy in Advanced MelanomaSemantic proximity Read ↗

Immunotherapy: HLA-1 genotype influences response to checkpoint inhibitors.Semantic proximity Read ↗

Probable HLA-mediated immunoediting of JAK2 V617F-driven oncogenesis.Semantic proximity Read ↗

Deregulation of HLA-I in cancer and its central importance for immunotherapySemantic proximity Read ↗

Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitor as first-line therapySemantic proximity Read ↗

Synergy of HLA class I and II shapes the timing of antitumor immune responseSemantic proximity Read ↗

Role of altered expression of HLA class I molecules in cancer progression.Semantic proximity Read ↗

Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy.Semantic proximity Read ↗

Genotyping Natural Killer Immune Checkpoints to Discover Biomarkers of Response.Semantic proximity Read ↗

Implication of Soluble HLA-G and HLA-G +3142G/C Polymorphism in Breast Cancer Patients Receiving Adjuvant Therapy in Tanzania.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.